deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03292809

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)

Sponsor: Novaliq GmbH

Conditions Dry Eye Disease
Interventions CyclASol topical ocular, eye drops Vehicle topical ocular, eye drops
Updated 14 times since 2017 Last updated: Dec 21, 2022 Started: Oct 19, 2017 Primary completion: May 22, 2018 Completion: Jun 20, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Dry Eye Disease and is currently completed. Novaliq GmbH leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jul 2019 · 8 months · monthly snapshot~Jul 2019 – ~Dec 2019 · 5 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2022 · 18 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2_PHASE3

  5. Jun 2021 — Dec 2022 [monthly]

    Completed PHASE2_PHASE3

▶ Show 9 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  3. Jul 2019 — Dec 2019 [monthly]

    Completed PHASE2_PHASE3

  4. Nov 2018 — Jul 2019 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE2_PHASE3

  8. Nov 2017 — Jan 2018 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet Recruiting → Recruiting

  9. Oct 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novaliq GmbH
Data source: Novaliq GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations